

## MEDICAL POLICY STATEMENT INDIANA MEDICAID

| Policy Name                       |                | Policy Number | Effective Date        |
|-----------------------------------|----------------|---------------|-----------------------|
| Transcranial Magnetic Stimulation |                | MM-0236       | 03/01/2021-03/31/2022 |
| Policy Type                       |                |               |                       |
| <b>MEDICAL</b>                    | Administrative | Pharmacy      | Reimbursement         |

Medical Policy Statements prepared by CareSource and its affiliates are derived from literature based on and supported by clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures.

Medical Policy Statements prepared by CareSource and affiliates do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced in the Medical Policy Statement. If there is a conflict between the Medical Policy Statement and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination.

According to the rules of Mental Health Parity Addiction Equity Act (MHPAEA), coverage for the diagnosis and treatment of a behavioral health disorder will not be subject to any limitations that are less favorable than the limitations that apply to medical conditions as covered under this policy.

## Table of Contents

|  |   |
|--|---|
| <a href="#">A. Subject</a>                 | 2 |
| <a href="#">B. Background</a>              | 2 |
| <a href="#">C. Definitions</a>             | 2 |
| <a href="#">D. Policy</a>                  | 2 |
| <a href="#">E. Conditions of Coverage</a>  | 4 |
| <a href="#">F. Related Policies/Rules</a>  | 4 |
| <a href="#">G. Review/Revision History</a> | 4 |
| <a href="#">H. References</a>              | 4 |



A. Subject  
**Transcranial Magnetic Stimulation**

B. Background


Transcranial Magnetic Stimulation was originally introduced in 1985 as a noninvasive treatment that is used for treating major depressive disorder. Transcranial Magnetic Stimulation is a technique that sends brief repetitive pulses of magnetic energy to the scalp via a large electromagnetic coil. This technique generates a low level of electrical stimulation. The amount of electricity created by this type of stimulation is very small and cannot be felt by the patient but is still strong enough to flow into the brain without seizures or need for anesthesia. The electric charges cause the neurons to become active and lead to the release of neurotransmitters such as serotonin, norepinephrine and dopamine.

C. Definitions

- **Depression:** a mental disorder that is characterized by alterations in mood secondary to psychological, social and biological factors. In the United States, by the year 2020, depressive illness will be the second leading cause of disability.
- **Adequate course of an antidepressant drug:** taking a drug for a duration of at least 4 weeks at the maximum dose for the specific antidepressant as approved by the FDA, or, documentation exists that higher doses were not tolerated when the dose is less than the FDA-approved maximum.
- **Augmentation therapy:** a drug regimen that consist of treating a patient with more than one drug, one of which is not an antidepressant, to increase therapeutic outcomes.
- **Dysthymia:** a form of depression that inhibits a person's ability to function at a high level or to feel well secondary to long-term, chronic symptoms of depression. This type of depression does not disable the person.
- **Depression Rating Scale:** Scales that have been standardized for national use to reliable assess the range of symptoms that are most commonly observed in adults with major depression. There are many rating scales available; however, listed below are the most commonly used scales that comprehensively survey the type and magnitude of symptom burden present:
  - Beck Depression Inventory (BDI)
  - Geriatric Depression Scale (GDS)
  - Hamilton Depression Rating Scale (HAM-D)
  - Personal Health Questionnaire Depression Scale (PHQ-9)
  - Quick Inventory of Depressive Symptomatology (QIDS)
- **Major Depressive Disorder:** a combination of depressive symptoms that become so severe that they are disabling and make daily functioning impossible.

D. Policy


- I. Prior authorization is required.
- II. TMS is considered medically necessary when ALL of the following criteria are met:
  - A. Member is 18 years of age or older AND



- B. Member has a confirmed diagnosis of treatment-resistant severe depressive disorder (single or recurrent episode); AND
- C. ONE or more of the following:
  - 1. The patient has demonstrated resistance to treatment with psychopharmacologic agents as evidenced by a lack of clinically significant response to four trials of such agents, in the current depressive episode, from at least two different agent classes. (At least one of the treatment trials must have been administered as an adequate course of mono- or poly-drug therapy; antidepressants involving standard therapeutic doses of at least 4 weeks duration)
  - 2. Inability to tolerate psychopharmacologic agents as evidenced by four trials of psychopharmacologic agents with distinct side effects
  - 3. History of response to TMS in a previous depressive episode (evidenced by a greater than 50% improvement in a standard rating scale for depression symptoms)
  - 4. Is currently receiving or is a candidate for and has declined electroconvulsive therapy (ECT), and TMS is considered a less invasive treatment optionAND
- D. Have undergone a trial of an evidence-based psychotherapy known to be effective in the treatment of MDD of an adequate frequency and duration without significant improvement in depressive symptoms as documented by standardized rating scales that reliably measure depressive symptoms AND
- E. None of the following conditions or contraindications are present:
  - 1. Seizure disorder or any history of seizure (except those induced by electroconvulsive therapy or isolated febrile seizures in infancy without subsequent treatment or recurrence); OR
  - 2. Presence of acute or chronic psychotic symptoms or disorders (such as schizophrenia, schizophreniform or schizoaffective disorder) in the current depressive episode; OR
  - 3. Neurological conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, having a history of repetitive or severe head trauma, or with primary or secondary tumors in the central nervous system; OR
  - 4. Presence of an implanted magnetic-sensitive medical device located less than or equal to 30 centimeters from the transcranial magnetic stimulation magnetic coil or other implanted metal items, including but not limited to a cochlear implant, implanted cardioverter defibrillator, pacemaker, vagus nerve stimulator, or metal aneurysm clips or coils, staples, or stents OR
  - 5. Unstable medical disorderAND
- F. Last successful TMS treatment was greater than 30 days prior to requested start date

### III. Additional Criteria

- A. Transcranial magnetic stimulation is administered by an FDA cleared device for the treatment of major depressive disorder in a safe and effective manner according to the manufacturer's user manual and specified stimulation parameters.



- B. A treatment course of transcranial magnetic stimulation should not exceed: 5 days a week for 6 weeks (total of 30 sessions), followed by a 3 week taper of 3 treatments in 1 week, 2 treatments the next week, and 1 treatment in the last week.
- C. TMS can be performed under the direction of a licensed psychiatrist or neurologist who has experience in administering TMS therapy when it is within their scope of practice.
- D. The qualified provider must personally supervise the initial individual motor threshold determinations, treatment parameter definition, and course of TMS treatment planning.
- E. Subsequent delivery and management of TMS sessions may be performed by the qualified provider or an appropriately trained technician under the direct supervision of the qualified provider ensuring the patient has someone in attendance at all times during the TMS session.

E. Conditions of Coverage

F. Related Policies/Rules

G. Review/Revision History

| DATE           |                                 | ACTION   |
|----------------|---------------------------------|--|
| Date Issued    | 11/01/2018                      |  |
| Date Revised   | 01/01/2019<br>10/02/2019<br>TBD | Clarified PA requirement, Changed definition of adequate trial, Added IIA, IIC4, IID. IIE5, IIF, IIIC, IIID, IIIE  |
| Date Effective | 03/01/2021                      |  |
| Date Achieved  | 03/31/2022                      | This Policy is no longer active and has been archived. Please note that there could be other Policies that may have some of the same rules incorporated and CareSource reserves the right to follow CMS/State/NCCI guidelines without a formal documented Policy |

H. References

1. "Brain Stimulation Therapies." *National Institute of Mental Health*, U.S. Department of Health and Human Services, June 2016, <https://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies.shtml>.
2. Holtzheimer, P. E., MD, Roy-Byrne, P. P., MD, & Solomon, D., MD. "Technique for Performing Transcranial Magnetic Stimulation (TMS)." *UpToDate*, Aug. 2019, <https://www.uptodate.com/contents/technique-for-performing-transcranial-magnetic-stimulation-tms>.
3. Perera, T, et al. "The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder." *Brain Stimulation*, 2016AD, pp. 336–346., doi:10.1016/j.brs.2016.03.010.
4. ICHP bulletin Indiana Health Coverage Programs February 21, 2019. Retrieved 10/30/2020 from: [www.provider.indianamedicaid.com](http://www.provider.indianamedicaid.com)

**The Medical Policy Statement detailed above has received due consideration as defined in the Medical Policy Statement Policy and is approved.**

*Independent medical review – 6/2018*

IN-MED-P-353479

Issue Date 11/01/2018

OMPP Approved 12/01/2020